Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Engineering Sequential Mutations into Human HSPCs Yields an Aggressive Myeloid Malignancy Allowing for Interrogation of Preleukemic Transformation

Cailin T Collins, Yusuke Nakauchi, Thomas Koehnke, James S Chavez, Suyoun Choi, Rajiv Sharma, Feifei Zhao, Ravindra Majeti

Blood (2023) 142 (Supplement 1): 953.

https://doi.org/10.1182/blood-2023-187422

Published: 2023

Journal Articles

Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

Ruwan Gunaratne, Crystal Zhou, Jesse W. Tai, Matthew Schwede, Kailee Tanaka, Matthew Alkaitis, Raymond Yin, Brian J. Sworder, Gabriel Mannis, Ravindra Majeti, Michael S. Khodadoust, David M. Kurtz, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 4307.

https://doi.org/10.1182/blood-2023-181459

Published: 2023

Journal Articles

The Shifting Prognosis of FLT3 Mutations in Acute Myeloid Leukemia in the Era of Targeted Therapy: A Real-World Study Using Large-Scale Electronic Health Record Data

Matthew Schwede, Gladys Rodriguez, Solomon Henry, Douglas Wood, Gabriel Mannis, Ravindra Majeti, Jonathan Chen, Eran Bendavid, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 958.

https://doi.org/10.1182/blood-2023-187725

Published: 2023

Journal Articles

Phase 1b/2 Trial of Enasidenib in Lower-Risk MDS and Nonproliferative CMML without Isocitrate Dehydrogenase Type 2 Mutations

Eric Kuo, Veronica Santiago, Kailee Tanaka, Vikram Puram, Crystal Zhou, Jesse W. Tai, Gabriel Mannis, Ravindra Majeti, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 1879.

https://doi.org/10.1182/blood-2023-187644

Published: 2023

Journal Articles

Serum Amyloid A1 (SAA1) Secreted By the Stromal Microenvironment Drives Malignant Clonal Proliferation in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Brian Chernak, Marta Galan-Diez, Abdullah Mahmood Ali, Alvaro Cuesta-Dominguez, Ziwei Chen, Thomas Koehnke, Ravindra Majeti, Martin Carroll, Azra Raza, Stavroula Kousteni

Blood (2023) 142 (Supplement 1): 4118.

https://doi.org/10.1182/blood-2023-174485

Published: 2023

Journal Articles

BCOR Loss Confers Increased Stemness and Partially Rescues RUNX1-Deficient Phenotypes in Human Hematopoietic Stem and Progenitor Cells

Kendra K Jackson, Amy C Fan, Daiki Karigane, Feifei Zhao, Cailin T Collins, Yusuke Nakauchi, Kensuke Kayamori, Athreya S Rangavajhula, Thomas Koehnke, Ravindra Majeti

Blood (2023) 142 (Supplement 1): 946.

https://doi.org/10.1182/blood-2023-187865

Published: 2023

Journal Articles

Harnessing Artificial Intelligence for Risk Stratification in Acute Myeloid Leukemia (AML): Evaluating the Utility of Longitudinal Electronic Health Record (EHR) Data Via Graph Neural Networks

Riya Sinha, Matthew Schwede, Ben Viggiano, David Kuo, Solomon Henry, Douglas Wood, Gabriel Mannis, Ravindra Majeti, Jonathan Chen, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 960.

https://doi.org/10.1182/blood-2023-190151

Published: 2023

Journal Articles

ASXL1 Truncating Mutations Drive Leukemic Resistance to T Cell Attack

Blood (2023) 142 (Supplement 1): 364.

https://doi.org/10.1182/blood-2023-189177

Published: 2023

Journal Articles

Intra-Leukemic IFNγ Signaling Mediates Cell Cycle Suppression and Chemoresistance in AML

Daiki Karigane, Amy C Fan, Kensuke Kayamori, Yusuke Nakauchi, Thomas Koehnke, Athreya S Rangavajhula, Asiri Ediriwickrema, Ravindra Majeti

Blood (2023) 142 (Supplement 1): 406.

https://doi.org/10.1182/blood-2023-181430

Published: 2023

Journal Articles

Gene Correction of DNMT3A:R882H in Primary Human AML Demonstrates That This Mutation Is Not Required for Disease Maintenance, but Is Associated with Increased Leukemia Stem Cell Frequency

Thomas Koehnke, Daiki Karigane, Eleanor Hilgart, Kensuke Kayamori, Amy C Fan, Cailin T Collins, Fabian P Suchy, Athreya S Rangavajhula, Yang Feng, Yusuke Nakauchi, Eduardo Martinez-Montes, Michael Koldobskiy, Andy Feinberg, Ravindra Majeti

Blood (2023) 142 (Supplement 1): 579.

https://doi.org/10.1182/blood-2023-186440

Published: 2023

Journal Articles

Single-cell genomics in AML: extending the frontiers of AML research

Asiri Ediriwickrema, Andrew J. Gentles, Ravindra Majeti

Blood (2023) 141 (4): 345–355.

https://doi.org/10.1182/blood.2021014670

Published: 2023

Journal Articles

Targeting IDH1-Mutated Pre-Leukemic Hematopoietic Stem Cells in Myeloid Disease, Including CCUS and AML

Niklas Landberg, Thomas Koehnke, Yusuke Nakauchi, Amy Fan, Daiki Karigane, Daniel Thomas, Ravindra Majeti

Blood (2022) 140 (Supplement 1): 2234–2235.

https://doi.org/10.1182/blood-2022-159617

Published: 2022

Journal Articles

Single Cell Analysis of Adult Human Hematopoietic Stem and Progenitor Cells Identifies a Novel Lymphoid Primed Multipotent Progenitor That Expands in Relapsed Acute Myeloid Leukemia

Asiri Ediriwickrema, Bogdan A. Luca, Aaron M Newman, Andrew J Gentles, Ravindra Majeti

Blood (2021) 138 (Supplement 1): 3259.

https://doi.org/10.1182/blood-2021-148993

Published: 2021

Journal Articles

Cytokine Rescue and Targeting of Inflammation-Sensitive RUNX1 Deficient Human CD34 + Hematopoietic Stem and Progenitor Cells

Amy Fan, Armon Azizi, BS, Kevin Nuno, BS, Yusuke Nakauchi, MD PhD, Feifei Zhao, MD, Andreas Reinisch, MD PhD, David Cruz Hernandez, MS, Ravindra Majeti, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137173

Published: 2020

Journal Articles

Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2

Ritika Dutta, BS, Tian Y Zhang, MD PhD, Thomas Koehnke, MD, Daniel Thomas, MD PhD, Eric Gars, MD, Melissa Stafford, Yusuke Nakauchi, MD PhD, Satinder Kaur, BS, Raymond Yin, Anupama Narla, MD, Ravindra Majeti, MD PhD

Blood (2019) 134 (Supplement_1): 540.

https://doi.org/10.1182/blood-2019-124551

Published: 2019

Journal Articles

Reprogramming Leukemia Cells into Antigen Presenting Cells As a Novel Cancer Vaccination Immunotherapy

Miles Hamilton Linde, BS, BA, Christopher G Dove, Sarah F Gurev, Paul Phan, Feifei Zhao, MD, Lindsay P Miller, Ravindra Majeti, MD PhD

Blood (2019) 134 (Supplement_1): 3217.

https://doi.org/10.1182/blood-2019-128577

Published: 2019

Journal Articles

RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9

James Y Chen, MD PhD, Kelly Marie McKenna, BS, Timothy S Choi, BS, Jiaqi Duan, MS, Lynette Brown, MSc, Jennifer J Stewart, PhD, Kavitha Sompalli, MS, Paresh Vyas, Stanley Schrier, MD, Ravindra Majeti, MD PhD, Irving L Weissman, MD, Kyle Elrod, BS, Mark Ping Chao, MD PhD, Chris H Takimoto, MD PhD, Jie Liu, PhD MD, Jens-Peter Volkmer, MD

Blood (2018) 132 (Supplement 1): 2327.

https://doi.org/10.1182/blood-2018-99-115674

Published: 2018

Journal Articles

Human Acute Myeloid Leukemia Inhibits Normal Erythroid Differentiation through the Paracrine Effects of IL-6

Tian Y Zhang, MD PhD, Ritika Dutta, BS, Feifei Zhao, MD, Ravindra Majeti, MD PhD

Blood (2018) 132 (Supplement 1): 911.

https://doi.org/10.1182/blood-2018-99-119297

Published: 2018

Journal Articles

Azacitidine and Ascorbate Inhibit the Competitive Outgrowth of Human TET2 Mutant HSPCs in a Xenograft Model of Pre-Leukemia

Yusuke Nakauchi, MD PhD, Daniel Thomas, MD PhD, Rajiv Sharma, PhD, M. Ryan Corces, PhD, Andreas Reinisch, MD PhD, David Cruz, MS, Thomas Koehnke, MD PhD, Daiki Karigane, MDPhD, Amy Fan, BS, Ravindra Majeti, MD PhD

Blood (2018) 132 (Supplement 1): 887.

https://doi.org/10.1182/blood-2018-99-113907

Published: 2018

Journal Articles

IDH1 Mutant AML Is Susceptible to Targeting De Novo Lipid Synthesis Independent of 2-Hydroxyglutarate and Has a Distinct Metabolic Profile from IDH2 Mutant AML

Daniel Thomas, MD PhD, Yusuke Nakauchi, MD PhD, Manhong Wu, PhD, Ming Zheng, PhD, Subarna Sinha, PhD, David Dill, PhD, Gary Peltz, MD PhD, Ravindra Majeti, MD PhD

Blood (2018) 132 (Supplement 1): 440.

https://doi.org/10.1182/blood-2018-99-115040

Published: 2018

NARROW

Engineering Sequential Mutations into Human HSPCs Yields an Aggressive Myeloid Malignancy Allowing for Interrogation of Preleukemic Transformation

Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

The Shifting Prognosis of FLT3 Mutations in Acute Myeloid Leukemia in the Era of Targeted Therapy: A Real-World Study Using Large-Scale Electronic Health Record Data

Phase 1b/2 Trial of Enasidenib in Lower-Risk MDS and Nonproliferative CMML without Isocitrate Dehydrogenase Type 2 Mutations

Serum Amyloid A1 (SAA1) Secreted By the Stromal Microenvironment Drives Malignant Clonal Proliferation in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

BCOR Loss Confers Increased Stemness and Partially Rescues RUNX1-Deficient Phenotypes in Human Hematopoietic Stem and Progenitor Cells

Harnessing Artificial Intelligence for Risk Stratification in Acute Myeloid Leukemia (AML): Evaluating the Utility of Longitudinal Electronic Health Record (EHR) Data Via Graph Neural Networks

ASXL1 Truncating Mutations Drive Leukemic Resistance to T Cell Attack

Intra-Leukemic IFNγ Signaling Mediates Cell Cycle Suppression and Chemoresistance in AML

Gene Correction of DNMT3A:R882H in Primary Human AML Demonstrates That This Mutation Is Not Required for Disease Maintenance, but Is Associated with Increased Leukemia Stem Cell Frequency

Single-cell genomics in AML: extending the frontiers of AML research

Targeting IDH1-Mutated Pre-Leukemic Hematopoietic Stem Cells in Myeloid Disease, Including CCUS and AML

Single Cell Analysis of Adult Human Hematopoietic Stem and Progenitor Cells Identifies a Novel Lymphoid Primed Multipotent Progenitor That Expands in Relapsed Acute Myeloid Leukemia

Cytokine Rescue and Targeting of Inflammation-Sensitive RUNX1 Deficient Human CD34 + Hematopoietic Stem and Progenitor Cells

Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2

Reprogramming Leukemia Cells into Antigen Presenting Cells As a Novel Cancer Vaccination Immunotherapy

RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9

Human Acute Myeloid Leukemia Inhibits Normal Erythroid Differentiation through the Paracrine Effects of IL-6

Azacitidine and Ascorbate Inhibit the Competitive Outgrowth of Human TET2 Mutant HSPCs in a Xenograft Model of Pre-Leukemia

IDH1 Mutant AML Is Susceptible to Targeting De Novo Lipid Synthesis Independent of 2-Hydroxyglutarate and Has a Distinct Metabolic Profile from IDH2 Mutant AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only